Mounjaro maintenance dose after weight loss: what happens next

Step 1: recognising that goal weight is not the end of treatment

Many people finishing their titration phase assume that once the scale stops moving, the job is done and the medicine can quietly be phased out. That is a common and understandable assumption, and it is worth letting go of gently, because the clinical picture is different. The biological signals that drive weight regain (hunger hormones, a slower metabolic rate, increased appetite) do not permanently reset just because you hit a number on the scale. Tirzepatide works by mimicking two gut hormones, GIP and GLP-1, to reduce appetite and slow gastric emptying. When the medicine stops, those effects stop with it.

The SURMOUNT-1 trial, which followed thousands of adults with obesity across 72 weeks at doses up to 15 mg, showed substantial average weight loss during active treatment. Separate extension data from the tirzepatide programme consistently showed that a large proportion of lost weight returns within a year of discontinuation. This is not a failure of the person; it reflects how obesity works as a long-term condition. The practical upshot is that most people who have reached their goal on Mounjaro need to stay on some dose of it to maintain what they have achieved.

You can read more about life on Mounjaro after reaching your target weight for a fuller discussion of what long-term treatment looks like in practice.

Step 2: finding the right maintenance dose with your prescriber

There is no universally agreed maintenance dose of Mounjaro after weight loss. The licensed dose range runs from 2.5 mg to 15 mg, and the prescriber's task at this stage shifts from titrating upward to identifying the lowest dose that sustains your result. For some people that is 10 mg or 15 mg. For others, weight stays stable at 7.5 mg or 5 mg once the active loss phase is over and the body has adjusted.

What the prescriber looks at: how stable your weight has been over the most recent 8–12 weeks, whether side effects at your current dose are tolerable for the long term, your overall health picture, and any changes in weight-related conditions like blood pressure or blood sugar. Dose reductions are possible but are handled cautiously. Dropping too quickly can trigger gradual regain, so changes tend to happen in small steps with a monitoring window between them.

If you are curious whether weight loss continues at a lower dose or plateaus, the page on whether you lose weight on a maintenance dose of Mounjaro addresses exactly that question.

The broader question of how goal weight affects dose decisions is also covered in depth on our site.

Step 3: what actually happens to the dose in practice

In a typical maintenance conversation, the prescriber will look at three scenarios. First: weight is stable on the current dose with manageable side effects. The recommendation here is usually to stay put. Second: weight is stable but side effects at the top dose feel burdensome for ongoing use. The prescriber may trial a step down, monitoring weight over the next four to eight weeks. Third: weight has started creeping back despite adherence. That can be a signal to re-examine lifestyle factors, review other medicines, or occasionally trial a step back up if it was previously well tolerated.

Notably, NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has been achieved after six months at the highest tolerated dose, continuing treatment should be reviewed. The same scrutiny applies in reverse at the maintenance stage: if weight is climbing despite a stable dose, that review conversation needs to happen sooner rather than later.

Costs across different doses vary, and if you are planning for the long term it is worth reading about what Mounjaro costs through a private prescription so there are no surprises as your dose picture becomes clearer.

Step 4: keeping maintenance clinically supervised

The practical point that is easy to overlook: none of the steps above happen outside a clinical relationship. Mounjaro is a prescription-only medicine. Adjusting your own dose between pens, skipping doses to stretch supply, or switching down because you have read something online are all approaches that bypass the oversight the medicine requires. Every time someone at nume continues their treatment, a GPhC-registered Independent Prescriber reads that repeat (not a checkbox, a person) before anything is dispensed.

For context on the specific lower doses that sometimes come up in maintenance conversations, the pages on how Mounjaro maintenance dosing works and on whether 2.5 mg has a role in long-term maintenance both go into detail worth reading before your next consultation. The 5 mg dose page covers what that pen's role typically looks like, including in the maintenance context.

If you want to understand all of nume's treatment options in one place, the weight-loss treatment overview sets out what is available and who it suits. And if you are ready to talk through where your dose should go next, a prescriber at nume's consultation page is a good place to start that conversation.